Balaña-Fouce Rafael, Alvarez-Velilla Raquel, Fernández-Prada Christopher, García-Estrada Carlos, Reguera Rosa M
Departamento de Ciencias Biomédicas, Universidad de León, Campus de Vegazana s/n, 24071 León, Spain.
Int J Parasitol Drugs Drug Resist. 2014 Aug 24;4(3):326-37. doi: 10.1016/j.ijpddr.2014.07.006. eCollection 2014 Dec.
The Trypanosomatidae family, composed of unicellular parasites, causes severe vector-borne diseases that afflict human populations worldwide. Chagas disease, sleeping sickness, as well as different sorts of leishmaniases are amongst the most important infectious diseases produced by Trypanosoma cruzi, Trypanosoma brucei and Leishmania spp., respectively. All these infections are closely related to weak health care services in low-income populations of less developed and least economically developed countries. Search for new therapeutic targets in order to hit these pathogens is of paramount priority, as no effective vaccine is currently in use against any of these parasites. Furthermore, present-day chemotherapy comprises old-fashioned drugs full of important side effects. Besides, they are prone to produce tolerance and resistance as a consequence of their continuous use for decades. DNA topoisomerases (Top) are ubiquitous enzymes responsible for solving the torsional tensions caused during replication and transcription processes, as well as in maintaining genomic stability during DNA recombination. As the inhibition of these enzymes produces cell arrest and triggers cell death, Top inhibitors are among the most effective and most widely used drugs in both cancer and antibacterial therapies. Top relaxation and decatenation activities, which are based on a common nicking-closing cycle involving one or both DNA strands, have been pointed as a promising drug target. Specific inhibitors that bind to the interface of DNA-Top complexes can stabilize Top-mediated transient DNA breaks. In addition, important structural differences have been found between Tops from the Trypanosomatidae family members and Tops from the host. Such dissimilarities make these proteins very interesting for drug design and molecular intervention. The present review is a critical update of the last findings regarding trypanosomatid's Tops, their new structural features, their involvement both in the physiology and virulence of these parasites, as well as their use as promising targets for drug discovery.
锥虫科由单细胞寄生虫组成,可引发严重的媒介传播疾病,困扰着全球人类。恰加斯病、昏睡病以及不同类型的利什曼病分别是由克氏锥虫、布氏锥虫和利什曼原虫属引发的最重要的传染病。所有这些感染都与欠发达和最不发达经济体低收入人群的医疗服务薄弱密切相关。由于目前尚无针对这些寄生虫的有效疫苗,寻找新的治疗靶点以攻克这些病原体至关重要。此外,当今的化疗药物都是老式药物,副作用很大。此外,由于数十年的持续使用,它们容易产生耐受性和抗药性。DNA拓扑异构酶(Top)是普遍存在的酶,负责解决复制和转录过程中产生的扭转张力,以及在DNA重组过程中维持基因组稳定性。由于抑制这些酶会导致细胞停滞并引发细胞死亡,拓扑异构酶抑制剂是癌症和抗菌治疗中最有效、使用最广泛的药物之一。基于涉及一条或两条DNA链的常见切口-封闭循环的拓扑异构酶松弛和解连环活性已被指出是一个有前景的药物靶点。与DNA-拓扑异构酶复合物界面结合的特异性抑制剂可稳定拓扑异构酶介导的瞬时DNA断裂。此外,已发现锥虫科家庭成员的拓扑异构酶与宿主的拓扑异构酶之间存在重要的结构差异。这些差异使得这些蛋白质在药物设计和分子干预方面非常有趣。本综述对锥虫拓扑异构酶的最新研究结果、它们的新结构特征、它们在这些寄生虫的生理学和毒力中的作用,以及它们作为有前景的药物发现靶点的应用进行了批判性更新。